Clinigen Group plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Peter Allen, was filed 28 Oct 2020.
Clinigen Group plc: what insiders have been doing
Clinigen Group plc is a listed company. Its insiders report their share dealings to RNS (LSE). Clinigen Group plc has had no insider filing for more than a year; the last one goes back to 4 October 2021.
The full history, which starts in 2016, counts 7 purchases against 14 sales.
Every figure here comes from the filings published by RNS (LSE) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
- 118,110 sharesLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:4132839
- 5,000 shares@ £6.09100.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:3761307-0Canonical exit: 25 Jan 2021 (T+90)
- 2,000 shares@ £6.0352100.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:3761307-1Canonical exit: 25 Jan 2021 (T+90)
- 1,000 shares@ £6.0097100.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:3761307-2Canonical exit: 25 Jan 2021 (T+90)
- 7,716 shares@ £6.0699100.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:3761307-3Canonical exit: 25 Jan 2021 (T+90)
- 7,000 shares@ £6.0724100.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:3761307-4Canonical exit: 25 Jan 2021 (T+90)
- 5,000 shares@ £0.0887100.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:3617970
- 3,900 shares@ £8.93100.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20190919123721_14233794_20200326185203176_15087Canonical exit: 18 Dec 2019 (T+90)
- 4,955 shares@ £10.17100.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20171124092624_13443128_20200330131534882_20305
- 17,360 shares@ £11.3152.6% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20171101155145_13417218_20200330131533563_1276
- 100,000 shares@ £11.5061.2% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20171016081601_13397387_20200330131537810_10268
- 15,498 shares@ £11.4747.4% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20171005151820_13387758_20200330131537250_4106-0
- 9,471 shares@ £11.50100.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20171005151820_13387758_20200330131537250_4106-1
- 250,000 shares@ £10.929646.4% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20171003103900_13384065_20200330131537139_1669
- 200,000 shares@ £8.42528.8% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20170630090101_13279318_20200330131523549_25319
- 500,000 shares@ £8.7521.2% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20170623091812_13271164_20200330131522711_19067
- 4,875 shares@ £4.42100.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20170601113602_13245868_20200330131521887_954
- 43,000 sharesLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20170509154737_13219646_20200330131530812_7135
- 200,000 shares@ £7.1724.8% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20161114094401_013033967_20200330143612367_10924
- 97,246 shares@ £7.5038.8% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20161019080002_013005855_20200330143616445_13819-0
- 2,200,000 shares@ £7.5078.8% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20161019080002_013005855_20200330143616445_13819-1
- 160,139 shares@ £7.7397.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20161005080003_012990308_20200330143615942_2948
- 5,100 shares@ £7.283.0% of flowLondon Stock Exchange, AIMISIN GB00B89J2419FCA-NSM:LSE20161003080001_012986845_20200330143615827_426
- 11,296 shares@ £5.18100.0% of flowFCA-NSM:LSE20160516160443_012817898_20200330143609740_11236Canonical exit: 14 Aug 2016 (T+90)
24 of 24 declarations
About Clinigen Group plc
Clinigen Group plc is a UK-based company specializing in the provision of pharmaceuticals and related services. It focuses on providing access to treatments for patients worldwide.
